nach oben

Erschienen in:

01.12.2016 | Research Article

Neutrophil to lymphocyte ratio associated with prognosis of lung cancer

verfasst von: V. Bar-Ad, J. Palmer, L. Li, Y. Lai, B. Lu, R. E. Myers, Z. Ye, R. Axelrod, J. M. Johnson, M. Werner-Wasik, S. W. Cowan, N. R. Evans, B. T. Hehn, C. C. Solomides, C. Wang

Erschienen in: Clinical and Translational Oncology | Ausgabe 6/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Many studies recently focus on complicated and expensive genomic tests, but the prognostic values of biochemical markers which are easily obtained in clinics are largely overlooked and without further exploration. This study assesses the association of neutrophil–lymphocyte-ratio (NLR) with prognosis of lung cancer patients.

Methods

In 1032 patients with histologically confirmed lung cancer, the association of pretreatment NLR values with overall survival (OS) was evaluated using a Cox proportional hazards model and the temporal relationship of longitudinal NLR was assessed using a mixed effects model.

Results

Compared to the patients with a low pretreatment NLR value, those with elevated NLR exhibited a statistically significant worse OS with a hazard ratio (HR) of 1.50 (P < 0.0001) after adjusting for age, gender, race, smoking status, drinking status, tumor stage, tumor grade, histology, and treatments. A significant trend of increasing HRs along with increasing NLR values was observed. The increased risk of death conferred by pretreatment NLR values reached a peak level around 2 years after diagnosis. Moreover, in longitudinal analysis, we observed a trend of dramatically increased NLR values in patients who died during follow-up, but stable NLR values in those who were still alive, with a significant interaction of death–alive status with follow-up time (P < 0.0001).

Conclusions

Elevated NLR is a potential biomarker to identify lung cancer patients with poor prognosis and should be validated in a future clinical trial.

Nur mit Berechtigung zugänglich

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.CrossRefPubMed

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30.CrossRefPubMed

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.CrossRefPubMed

Orozco-Morales M, Soca-Chafre G, Barrios-Bernal P, Hernandez-Pedro N, Arrieta O. Interplay between Cellular and Molecular Inflammatory Mediators in Lung Cancer. Mediators Inflamm. 2016;2016:3494608.CrossRefPubMedPubMedCentral

Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883–99.CrossRefPubMedPubMedCentral

O’Callaghan DS, O’Donnell D, O’Connell F, O’Byrne KJ. The role of inflammation in the pathogenesis of non-small cell lung cancer. J Thorac Oncol. 2010;5(12):2024–36.CrossRefPubMed

Wu Y, Zhou BP. Inflammation: a driving force speeds cancer metastasis. Cell Cycle. 2009;8(20):3267–73.CrossRefPubMedPubMedCentral

Zahorec R. Ratio of neutrophil to lymphocyte counts-rapid and simple parameter of systemic inflammation and stress in critically ill. Bratisl Lek Listy. 2001;102(1):5–14.PubMed

Hung HY, Chen JS, Yeh CY, Changchien CR, Tang R, Hsieh PS, et al. Effect of preoperative neutrophil-lymphocyte ratio on the surgical outcomes of stage II colon cancer patients who do not receive adjuvant chemotherapy. Int J Colorectal Dis. 2011;26(8):1059–65.CrossRefPubMed

10.

Templeton AJ, McNamara MG, Seruga B, Vera-Badillo FE, Aneja P, Ocana A, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106(6):dju124.CrossRefPubMed

11.

Luo G, Guo M, Liu Z, Xiao Z, Jin K, Long J, et al. Blood neutrophil-lymphocyte ratio predicts survival in patients with advanced pancreatic cancer treated with chemotherapy. Ann Surg Oncol. 2015;22(2):670–6.CrossRefPubMed

12.

Kakinuma T, Hwang ST. Chemokines, chemokine receptors, and cancer metastasis. J Leukoc Biol. 2006;79(4):639–51.CrossRefPubMed

13.

McColl SR, Paquin R, Menard C, Beaulieu AD. Human neutrophils produce high levels of the interleukin 1 receptor antagonist in response to granulocyte/macrophage colony-stimulating factor and tumor necrosis factor alpha. J Exp Med. 1992;176(2):593–8.CrossRefPubMed

14.

Vock DM, Davidian M, Tsiatis AA, Muir AJ. Mixed model analysis of censored longitudinal data with flexible random-effects density. Biostatistics. 2012;13(1):61–73.CrossRefPubMed

15.

Ries LA. Influence of extent of disease, histology, and demographic factors on lung cancer survival in the SEER population-based data. Semin Surg Oncol. 1994;10(1):21–30.CrossRefPubMed

16.

Blackstock AW, Herndon JE 2nd, Paskett ED, Perry MC, Graziano SL, Muscato JJ, et al. Outcomes among African-American non-African-American patients with advanced non-small-cell lung carcinoma report from the Cancer and Leukemia Group B. J Natl Cancer Inst. 2002;94(4):284–90.CrossRefPubMed

17.

Bryant AS, Cerfolio RJ. Impact of race on outcomes of patients with non-small cell lung cancer. J Thorac Oncol. 2008;3(7):711–5.CrossRefPubMed

18.

Blackstock AW, Herndon JE 2nd, Paskett ED, Miller AA, Lathan C, Niell HB, et al. Similar outcomes between African American and non-African American patients with extensive-stage small-cell lung carcinoma: report from the Cancer and Leukemia Group B. J Clin Oncol. 2006;24(3):407–12.CrossRefPubMed

19.

Albain KS, Unger JM, Crowley JJ, Coltman CA Jr, Hershman DL. Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group. J Natl Cancer Inst. 2009;101(14):984–92.CrossRefPubMedPubMedCentral

20.

Kawaguchi T, Takada M, Kubo A, Matsumura A, Fukai S, Tamura A, et al. Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: a comprehensive analysis of 26,957 patients with NSCLC. J Thorac Oncol. 2010;5(5):620–30.CrossRefPubMed

21.

Tomita M, Ayabe T, Chosa E, Nakamura K. Impact of smoking on outcome of resected lung adenocarcinoma. Gen Thorac Cardiovasc Surg. 2015;63(11):608–12.CrossRefPubMed

22.

Yu SL, Chen HY, Chang GC, Chen CY, Chen HW, Singh S, et al. MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell. 2008;13(1):48–57.CrossRefPubMed

23.

Orlow I, Park BJ, Mujumdar U, Patel H, Siu-Lau P, Clas BA, et al. DNA damage and repair capacity in patients with lung cancer: prediction of multiple primary tumors. J Clin Oncol. 2008;26(21):3560–6.CrossRefPubMedPubMedCentral

Titel: Neutrophil to lymphocyte ratio associated with prognosis of lung cancer
verfasst von: V. Bar-Ad
J. Palmer
L. Li
Y. Lai
B. Lu
R. E. Myers
Z. Ye
R. Axelrod
J. M. Johnson
M. Werner-Wasik
S. W. Cowan
N. R. Evans
B. T. Hehn
C. C. Solomides
C. Wang
Publikationsdatum: 01.12.2016
Verlag: Springer International Publishing
Erschienen in: Clinical and Translational Oncology / Ausgabe 6/2017
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-016-1593-y

Springer Medizin

Neutrophil to lymphocyte ratio associated with prognosis of lung cancer